Trial
NCT04203511
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Retifanlimab
Why stopped
Sponsor Strategic/Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-09